Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Toxicological information

Skin sensitisation

Currently viewing:

Administrative data

Endpoint:
skin sensitisation: in vivo (LLNA)
Type of information:
experimental study
Adequacy of study:
key study
Study period:
6 February - 3 June 2008
Reliability:
1 (reliable without restriction)
Rationale for reliability incl. deficiencies:
guideline study

Data source

Reference
Reference Type:
study report
Title:
Unnamed
Year:
2008
Report date:
2008

Materials and methods

Test guidelineopen allclose all
Qualifier:
according to guideline
Guideline:
EPA OPPTS 870.2600 (Skin Sensitisation)
Deviations:
no
Qualifier:
according to guideline
Guideline:
OECD Guideline 429 (Skin Sensitisation: Local Lymph Node Assay)
Deviations:
no
GLP compliance:
yes
Type of study:
mouse local lymph node assay (LLNA)

Test material

Constituent 1
Chemical structure
Reference substance name:
7-hydroxy-3-(4-methoxyphenyl)-4-benzopyrone
EC Number:
207-623-9
EC Name:
7-hydroxy-3-(4-methoxyphenyl)-4-benzopyrone
Cas Number:
485-72-3
Molecular formula:
C16H12O4
IUPAC Name:
7-hydroxy-3-(4-methoxyphenyl)-4H-chromen-4-one
Test material form:
solid: particulate/powder
Specific details on test material used for the study:
- Lot No. of test material: 07-170-FIL-2/3
- Appearance: White powder
- Expiration date: May 2010
- Purity: 98.4%
- Storage condition of test material: Room temperature

In vivo test system

Test animals

Species:
mouse
Strain:
CBA:J
Sex:
female
Details on test animals and environmental conditions:
TEST ANIMALS
- Source: Harlan Sprague-Dawley, Indianapolis, IN
- Females nulliparous and non-pregnant: yes
- Age at study initiation: Approx. 9 weeks old
- Weight at initial dose day: 19.4 - 23.9 g
- Housing: Suspended, wire bottom, stainless steel cage; 1 animal per cage
- Diet: PMI Feeds Inc. Formulab #5008; available ad libitum
- Water: Municipal water supply available ad libitum from automatic water system
- Acclimation period: At least 5 days
- Indication of any skin lesions: Not specified

ENVIRONMENTAL CONDITIONS
- Temperature (°C): 21 ± 3°C
- Humidity (%): 30 - 70%
- Air changes (per hr): 10 - 12 air changes/ hour
- Photoperiod (hrs dark / hrs light): 12 hour light/dark cycle

IN-LIFE DATES: 12 March 2008 To: 20 March 2008

Study design: in vivo (LLNA)

Vehicle:
propylene glycol
Concentration:
25 µL of an appropriate dilution (25% or 50%) of the test substance or 100% test substance moistened with propylene glycol
No. of animals per dose:
5 animals per dose
Details on study design:
MAIN STUDY

TREATMENT PREPARATION AND ADMINISTRATION:
The test substance was applied to the dorsum of both ears. The vehicle control group (5 females) was treated in the same way as the test animals but with vehicle alone (propylene glycol) instead of test substance. The positive control group (5 females) was treated with 90% alpha-hexylcinnamaldehyde in acetone: olive oil. The animals were treated once daily for 3 days.
All test and control animals were given a 2-day rest period on Days 4 and 5.
On Day 6 of the study, all test and control animals were injected in the tail vein with 250 µL of 0.01 M phosphate-buffered saline, pH 7.4 containing 20 µCi of [methyl,1,2-3H] Thymidine. Five hours after the injection, the animals were sacrificed, the draining auricular lymph nodes were excised and pairs from each individual animal were processed.
Incorporation of tritiated thymidine was measured by liquid scintillation counting as disintegrations per minute (DPM) from the paired lymph nodes of each animal and mean DPM/ animal was calculated for each group.

BODY WEIGHTS AND OBSERVATIONS:
Individual body weights were recorded on Day 1 prior to dosing and Day 6 prior to injection. All test and control animals were observed daily for clinical signs of toxicity and any signs of excessive irritation at the test site.
Positive control substance(s):
hexyl cinnamic aldehyde (CAS No 101-86-0)

Results and discussion

Positive control results:
The positive control test substance produced a stimulation index of ≥3 and is therefore considered a sensitiser.

In vivo (LLNA)

Resultsopen allclose all
Key result
Parameter:
SI
Value:
0.8
Test group / Remarks:
Test Group I - 25% test substance concentration
Key result
Parameter:
SI
Value:
1.4
Test group / Remarks:
Test Group II - 50% test substance concentration
Key result
Parameter:
SI
Value:
0.7
Test group / Remarks:
Test Group III - 100% test substance concentration
Cellular proliferation data / Observations:
STIMULATION INDEX
See Table 1

CLINICAL OBSERVATIONS:
All animals appeared normal for the duration of the study.

BODY WEIGHTS:
One Test Group 1 animal lost weight during the study.

Any other information on results incl. tables

Table 1: Stimulation Index (SI) or Test/Vehicle Control Ratio for each test group

Animal group

Test substance concentration

Average count per mouse (DPM)

Number of mice in group

Test/vehicle control ratio (SI)

Vehicle control

NA

379

5

NA

Test Group I

25%

307

5

0.8

Test Group II

50%

514

5

1.4

Test Group III

100%

275

5

0.7

Positive control

NA

8082

5

21.3*

NA – not applicable

* - positive control used to confirm animal sensitisation potential and validate procedures

ENVIRONMENT:

- Actual temperature: 20 - 21°C

- Actual relative humidity: 44 - 95% (Humidity was outside of the protocol range but did not affect the study outcome)

Applicant's summary and conclusion

Interpretation of results:
GHS criteria not met
Conclusions:
Formononetin produced a stimulation index of <3 in all groups of test animals and is therefore not considered a sensitiser.